Project Grant HT94252410646
Award Date
7/1/24
Completion Date
6/30/27
Dollars Obligated
$854K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94103, USA
Similar Awards
The Regents of the University of California, San Francisco (UCSF) has been awarded a $595,160 Project Grant by the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to translate a first-in-class PET radiotracer to assess ferroaddiction as a therapeutic vulnerability in advanced prostate cancer. The 3-year award, effective July 1, 2024, supports innovative biomedical research aimed at developing new diagnostic and treatment approaches for military personnel...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $1,453,501.00 Project Grant to The Regents of the University of California, San Francisco (UCSF) on June 1, 2024. The grant supports the development of "Targeted Theranostic Nanopolymers for Imaging and Alpha Radiopharmaceutical Therapy of Prostate Cancer" over a period of 3 years through May 31, 2027. As a leading academic medical center, UCSF will leverage its expertise in biomedical...
The University of California, San Francisco (UCSF) has been awarded a $1,202,087 federal Project Grant from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to investigate SSTR1 as a novel biomarker and therapeutic target in advanced prostate cancer. The award, effective July 1, 2024 through June 30, 2028, will enable UCSF researchers to conduct innovative scientific studies to develop new treatments for this challenging disease. As a leading academic...
This $1,211,127 Project Grant awarded by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports a research project by the University of California, San Francisco (UCSF) to investigate the importance of immune responses to prostate tumor antigens primed by a combination of radiation and immunotherapy. The 4-year project aims to advance understanding of how to leverage the body's immune system to improve treatments for prostate cancer. As...
This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $1,228,594.00 to the Regents of the University of California, San Francisco (UCSF) for research on bispecific antibody-drug conjugates against emerging targets in metastatic lethal prostate cancer. The award period is from April 15, 2024 to April 14, 2027. As a leading academic medical center and research institution, UCSF will leverage its...
The Department of the Army Medical Command awarded a $685,497 Project Grant to the Regents of the University of California, San Francisco through the Military Medical Research and Development program. The grant will fund a research project from July 2022 through July 2025 to develop GRANZYME B PET imaging as a novel method to assess T-cell activation in response to 177LU-PSMA-617 priming in metastatic castration-resistant prostate cancer. The Military Medical Research and Development program...
This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $1,615,000.00 to The Regents of the University of California, San Francisco (UCSF) to conduct research aimed at "DISCOVERING TRANSCRIPTIONAL DRIVERS OF THERAPY-RESISTANT METASTATIC PROSTATE CANCER". The award period runs from May 1, 2024 to April 30, 2027. As a leading academic medical center, UCSF has a strong track record of...
The Defense Health Agency awarded a $1,453,500.00 Project Grant to The Regents of the University of California, San Francisco (UCSF) under the Military Medical Research and Development program (CFDA 12.420). This 3-year grant, commencing on June 20, 2023, will support UCSF's research to profile and eliminate tumor subclones resistant to radioligand therapy. Through this project, UCSF aims to transform health care for Service Members and the American public by developing innovative and...
The Regents of the University of California, San Francisco was awarded a $484,500 Project Grant from the Defense Health Agency to support research titled "Synergistic Combination Treatment of Prostate Cancer Using CD46- Targeted Antibody-Drug Conjugate and Radioimmunotherapy." The two-year award beginning March 1, 2023 will fund the development of innovative medical solutions for prostate cancer through the Military Medical Research and Development program (CFDA 12.420). This program...
This Federal Project Grant award for $236,777.00 was provided by the Defense Health Agency to The Regents of the University of California, San Francisco (UCSF) under the Military Medical Research and Development program (CFDA 12.420). The funding supports RAPID HIGH RESOLUTION METABOLIC IMAGING FOR IMPROVED MANAGEMENT OF PATIENTS WITH GLIOMA, a research project aimed at developing advanced imaging techniques to better manage patients with glioma, a type of brain cancer. The award term runs...